Antengene Corporation Limited (HKG:6996)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Research Development and Commercialisation of Pharmaceutical Products	105.34M	91.95M	67.31M	160.14M	28.77M
Research Development and Commercialisation of Pharmaceutical Products Growth	14.56%	36.62%	-57.97%	456.62%	-
Total	105.34M	91.95M	67.31M	160.14M	28.77M
Total Growth	14.56%	36.62%	-57.97%	456.62%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Mainland China	85.73M	72.26M	56.70M	-	-
Mainland China Growth	18.64%	27.44%	-	-	-
Other Countries/Regions	19.61M	19.69M	10.61M	5.27M	238.00K
Other Countries/Regions Growth	-0.41%	85.69%	101.42%	2112.18%	-
Greater China	-	-	-	154.87M	28.53M
Greater China Growth	-	-	-	442.81%	-
Total	105.34M	91.95M	67.31M	160.14M	28.77M
Total Growth	14.56%	36.62%	-57.97%	456.62%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 6, 2026

Data Sources Report a data error